IL6 and diffuse large B-cell lymphoma: Our retrospective analysis demonstrated that rituximab-based therapy increased the expression of IL-6 in patients with DLBCL [32]; furthermore, the cell culture study demonstrated that rituximab significantly increased the expression of IL-6 in SU-DHL-4 cells both in protein and in mRNA levels with a concentration-dependent manner [32].